Creatinine-d5
Based on 1 Customer Validation
Creatinine-d5 is the deuterium labeled Creatinine. Creatinine (NSC13123) is an orally active, blood-brain barrier-permeable modulator of GABAA and NMDA receptors, with activities of antioxidation and metabolic regulation. Creatinine is generated via non-enzymatic conversion of creatine and phosphocreatine in muscle. Creatinine serum levels correlate with muscle mass, glomerular filtration rate, and extrarenal clearance, serving as an evaluation biomarker for renal function, muscle mass, and clinical outcomes, and used for perioperative renal risk assessment. In addition, Creatinine can induce specific Cryptococcus species to produce creatinine deiminase and act as their nitrogen source, while it can be secreted via renal tubules. Creatinine is widely used in research related to various diseases such as neurodegenerative diseases, psychiatric disorders, acute kidney injury, chronic kidney disease, and renal failure.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.93%
- 分子式: C4H2D5N3O
- 分子量:118.15
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
化学情報
-
非標識Cas 60-27-5
-
性状 Solid
-
分子量 118.15
-
分子式 C4H2D5N3O
-
Color White to off-white
-
SMILES
[2H]C([2H])(N1C(NC(C1([2H])[2H])=O)=N)[2H]
-
別名
NSC13123-d5
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
溶剤 & 溶解度
H2O : 33.33 mg/mL (282.10 mM; Need ultrasonic)
DMSO : 2.5 mg/mL (21.16 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
純度とドキュメンテーション
-
データシート (278 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
[2]. Fang J, et al. Creatinine promotes adipose tissue wasting in chronic kidney disease via creatine and futile creatine cycle. Mol Metab. 2025;98:102191. [Content Brief]
[3]. Allen PJ, et al. Creatine metabolism and psychiatric disorders: Does creatine supplementation have therapeutic value?. Neurosci Biobehav Rev. 2012;36(5):1442-1462. [Content Brief]
[4]. Polacheck I, et al. Creatinine metabolism in Cryptococcus neoformans and Cryptococcus bacillisporus. J Bacteriol. 1980;142(1):15-20. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / H2O | 1 mM | 8.4638 mL | 42.3191 mL | 84.6382 mL | 211.5954 mL |
| 5 mM | 1.6928 mL | 8.4638 mL | 16.9276 mL | 42.3191 mL | |
| 10 mM | 0.8464 mL | 4.2319 mL | 8.4638 mL | 21.1595 mL | |
| 15 mM | 0.5643 mL | 2.8213 mL | 5.6425 mL | 14.1064 mL | |
| 20 mM | 0.4232 mL | 2.1160 mL | 4.2319 mL | 10.5798 mL | |
| H2O | 25 mM | 0.3386 mL | 1.6928 mL | 3.3855 mL | 8.4638 mL |
| 30 mM | 0.2821 mL | 1.4106 mL | 2.8213 mL | 7.0532 mL | |
| 40 mM | 0.2116 mL | 1.0580 mL | 2.1160 mL | 5.2899 mL | |
| 50 mM | 0.1693 mL | 0.8464 mL | 1.6928 mL | 4.2319 mL | |
| 60 mM | 0.1411 mL | 0.7053 mL | 1.4106 mL | 3.5266 mL | |
| 80 mM | 0.1058 mL | 0.5290 mL | 1.0580 mL | 2.6449 mL | |
| 100 mM | 0.0846 mL | 0.4232 mL | 0.8464 mL | 2.1160 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Creatinine-d5 関連分類
HY-B0504S2 関連分類
Powered by Bioz